Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6

Mika K. Kaneko; Shinji Yamada; Shunsuke Itai; Yoshikazu Furusawa; Takuro Nakamura; Miyuki Yanaka; Saori Handa; Kayo Hisamatsu; Yoshimi Nakamura; Masato Fukui; Hiroyuki Harada; Yukinari Kato

doi:10.1016/j.bbrep.2018.07.003

Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6

Mika K. Kaneko, Shinji Yamada, Shunsuke Itai, Yoshikazu Furusawa, Takuro Nakamura, Miyuki Yanaka, Saori Handa, Kayo Hisamatsu, Yoshimi Nakamura, Masato Fukui, Hiroyuki Harada, Yukinari Kato

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The alpha-thalassemia/mental-retardation-syndrome-X-linked (ATRX) gene is located on the q arm of the X chromosome. ATRX gene mutations were first discovered in pancreatic neuroendocrine tumors, and subsequently in other cancer subtypes, including gliomas. Molecular subgrouping of gliomas has been more important than conventional histological classifications. Mutations in the isocitrate dehydrogenase (IDH), telomerase reverse transcriptase (TERT) promoter, and ATRX and the codeletion of chromosomes 1p/19q are used as biomarkers for diagnosing the subtypes of diffuse gliomas. We recently developed a sensitive monoclonal antibody (mAb) AMab-6 against ATRX by immunizing mice with recombinant human ATRX. AMab-6 can help to detect ATRX mutations via Western blotting and immunohistochemical analyses. In this study, we characterized the binding epitope of AMab-6 using enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunohistochemical analysis, and found that Gln2368 of ATRX is critical for AMab-6 binding to ATRX. Our findings could be applied to the production of more functional anti-ATRX mAbs.

Original language	English
Pages (from-to)	76-80
Number of pages	5
Journal	Biochemistry and Biophysics Reports
Volume	15
DOIs	https://doi.org/10.1016/j.bbrep.2018.07.003
Publication status	Published - 2018 Sept

Keywords

AMab-6
ATRX
Epitope mapping

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bbrep.2018.07.003

Cite this

@article{e990d81d0673488d9896bbadb1e5bd10,

title = "Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6",

abstract = "The alpha-thalassemia/mental-retardation-syndrome-X-linked (ATRX) gene is located on the q arm of the X chromosome. ATRX gene mutations were first discovered in pancreatic neuroendocrine tumors, and subsequently in other cancer subtypes, including gliomas. Molecular subgrouping of gliomas has been more important than conventional histological classifications. Mutations in the isocitrate dehydrogenase (IDH), telomerase reverse transcriptase (TERT) promoter, and ATRX and the codeletion of chromosomes 1p/19q are used as biomarkers for diagnosing the subtypes of diffuse gliomas. We recently developed a sensitive monoclonal antibody (mAb) AMab-6 against ATRX by immunizing mice with recombinant human ATRX. AMab-6 can help to detect ATRX mutations via Western blotting and immunohistochemical analyses. In this study, we characterized the binding epitope of AMab-6 using enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunohistochemical analysis, and found that Gln2368 of ATRX is critical for AMab-6 binding to ATRX. Our findings could be applied to the production of more functional anti-ATRX mAbs.",

keywords = "AMab-6, ATRX, Epitope mapping",

author = "Kaneko, {Mika K.} and Shinji Yamada and Shunsuke Itai and Yoshikazu Furusawa and Takuro Nakamura and Miyuki Yanaka and Saori Handa and Kayo Hisamatsu and Yoshimi Nakamura and Masato Fukui and Hiroyuki Harada and Yukinari Kato",

note = "Funding Information: This research was supported in part by AMED under Grant numbers: JP18am0101078 (Y.K.), JP18am0301010 (Y.K.), and JP18ae0101028 (Y.K.), and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and Grant Number 16K10748 (Y.K.). Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = sep,

doi = "10.1016/j.bbrep.2018.07.003",

language = "English",

volume = "15",

pages = "76--80",

journal = "Biochemistry and Biophysics Reports",

issn = "2405-5808",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6

AU - Kaneko, Mika K.

AU - Yamada, Shinji

AU - Itai, Shunsuke

AU - Furusawa, Yoshikazu

AU - Nakamura, Takuro

AU - Yanaka, Miyuki

AU - Handa, Saori

AU - Hisamatsu, Kayo

AU - Nakamura, Yoshimi

AU - Fukui, Masato

AU - Harada, Hiroyuki

AU - Kato, Yukinari

N1 - Funding Information: This research was supported in part by AMED under Grant numbers: JP18am0101078 (Y.K.), JP18am0301010 (Y.K.), and JP18ae0101028 (Y.K.), and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and Grant Number 16K10748 (Y.K.). Publisher Copyright: © 2018 The Authors

PY - 2018/9

Y1 - 2018/9

N2 - The alpha-thalassemia/mental-retardation-syndrome-X-linked (ATRX) gene is located on the q arm of the X chromosome. ATRX gene mutations were first discovered in pancreatic neuroendocrine tumors, and subsequently in other cancer subtypes, including gliomas. Molecular subgrouping of gliomas has been more important than conventional histological classifications. Mutations in the isocitrate dehydrogenase (IDH), telomerase reverse transcriptase (TERT) promoter, and ATRX and the codeletion of chromosomes 1p/19q are used as biomarkers for diagnosing the subtypes of diffuse gliomas. We recently developed a sensitive monoclonal antibody (mAb) AMab-6 against ATRX by immunizing mice with recombinant human ATRX. AMab-6 can help to detect ATRX mutations via Western blotting and immunohistochemical analyses. In this study, we characterized the binding epitope of AMab-6 using enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunohistochemical analysis, and found that Gln2368 of ATRX is critical for AMab-6 binding to ATRX. Our findings could be applied to the production of more functional anti-ATRX mAbs.

AB - The alpha-thalassemia/mental-retardation-syndrome-X-linked (ATRX) gene is located on the q arm of the X chromosome. ATRX gene mutations were first discovered in pancreatic neuroendocrine tumors, and subsequently in other cancer subtypes, including gliomas. Molecular subgrouping of gliomas has been more important than conventional histological classifications. Mutations in the isocitrate dehydrogenase (IDH), telomerase reverse transcriptase (TERT) promoter, and ATRX and the codeletion of chromosomes 1p/19q are used as biomarkers for diagnosing the subtypes of diffuse gliomas. We recently developed a sensitive monoclonal antibody (mAb) AMab-6 against ATRX by immunizing mice with recombinant human ATRX. AMab-6 can help to detect ATRX mutations via Western blotting and immunohistochemical analyses. In this study, we characterized the binding epitope of AMab-6 using enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunohistochemical analysis, and found that Gln2368 of ATRX is critical for AMab-6 binding to ATRX. Our findings could be applied to the production of more functional anti-ATRX mAbs.

KW - AMab-6

KW - ATRX

KW - Epitope mapping

UR - http://www.scopus.com/inward/record.url?scp=85049740993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049740993&partnerID=8YFLogxK

U2 - 10.1016/j.bbrep.2018.07.003

DO - 10.1016/j.bbrep.2018.07.003

M3 - Article

AN - SCOPUS:85049740993

SN - 2405-5808

VL - 15

SP - 76

EP - 80

JO - Biochemistry and Biophysics Reports

JF - Biochemistry and Biophysics Reports

ER -

Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this